I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK and Australia):

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

EAN 2021

-
12:00 PM
01:00 PM
Duration 5mins Virtual
A Randomized, Double-Blind, Placebo-Controlled, Gene-Delivery Clinical Trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne Muscular Dystrophy
Jerry R Mendell; Perry B. Shieh; Zarife Sahenk; Kelly Lehman; Linda P Lowes; Natalie Reash; Megan Iammarino; Lindsay N Alfano; Jeremy D Woods; Christy L Skura; Howard C Mao; Loretta A Staudt; Rachael A Potter; Danielle Griffin; Sarah Lewis; Larry Hu; Sameer Upadhyay; Teji Singh; Louise R Rodino-Klapac
05:00 PM
Duration 10mins Virtual
Safety of Ocrelizumab▼ in Patients With RRMS With Suboptimal Response to Prior DMTs: Data From the CASTING Study
Oreja-Guevara C, Wiendl H, Siva A, Kadner K, Kuenzel T, Buffels R, Vermersch P
05:30 PM
Duration 10mins Virtual
Effect of Ocrelizumab▼ on Cerebellar Atrophy in RMS and PPMS: Results from OPERA I/OPERA II and ORATORIO
Arnold DL, Assemlal HE, Traboulsee A, Kolind S, Sprenger T, Bar-Or A, Wolinksy J, Kappos L, Inglese M, Schneble HM, Magon S, Koendgen H, Bernasconi C, Gaetano L
01:15 PM
Duration 5mins Virtual
FIREFISH Parts 1 and 2: 24-Month safety and efficacy of risdiplam▼ in Type 1 SMA
Masson R, Boespflug-Tanguy O, Darras BT, Day JW, Deconinck N, Klein A, Mazurkiewicz-Bełdzińska M, Mercuri E, Rose K, Servais L, Vlodavets D, Xiong H, Zanoteli E, Dodman A, El-Khairi M, Gaki E, Gerber M, Gorni K, Kletzl H, Baranello G on behalf of the FIREFISH Working Group
Duration 5mins Virtual
JEWELFISH: Safety and pharmacodynamic data in non-naïve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam▼
Bruno C, Chiriboga CA, Duong T, Fischer D, Kirschner J, Mercuri E, Gerber M, Gorni K, Kletzl H, Carruthers I, Scalco RS, Warren F, Muntoni F on behalf of the JEWELFISH Study Group
Duration 5mins Virtual
RAINBOWFISH: A study of risdiplam▼ in newborns with presymptomatic spinal muscular atrophy (SMA)
Bertini E, Al-Muhaizea M, Farrar MA, Nelson L, Prufer A, Servais L, Wang Y, Zanoteli E, El-Khairi M, Gerber M, Gorni K, Kletzl H, Palfreeman L, Scalco RS, Finkel RS on behalf of the RAINBOWFISH Study Group
Duration 5mins Virtual
Pooled Safety Data from the risdiplam▼ clinical trial development program
Servais L, Baranello G, Bertini E, Chiriboga CA, Darras BT, Day JW, Deconinck N, Fischer D, Goemans N, Kirschner J, Klein A, Masson R, Mazurkiewicz-Bełdzińska M, Wang Y, Bader-Weder S, Gorni K, Jaber B, McIver T, Scalco RS, Mercuri E on behalf of the FIREFISH, SUNFISH and JEWELFISH Study Groups
03:15 PM
Duration 15mins Virtual
Roche Parkinson’s Disease Mobile Application v2 detects potential disease modifying effect of prasinezumab
Lipsmeier F, Taylor KI, Volkova-Volkmar E, Rukina D, Anzures-Cabrera J, Essioux L, Abt M, Lier B, Thomann AE, Svoboda H, Zago W, Pagano G, Postuma RB, Lindemann M
03:45 PM
Duration 15mins Virtual
A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): Results from Part 1 Week 52
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Zago W, Tripuraneni R, Boulay A, Vogt A, Boess FG, Nikolcheva T, Svoboda H, Britschgi M, Lipsmeier F, Lindemann M, Dziadek S, Azulay J, Mollenhauer B, Lopez Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Simuni TS, Gasser T, Poewe W, Kinney GG, Doody R, Fontoura P, Umbricht D, and Bonni A for the PASADENA Investigators and Prasinezumab Study Group
06:15 PM
Duration 15mins Virtual
Reliability and validity of passively measured gait, gestures from smartphones and smartwatches in Parkinson’s disease
Volkova-Volkmar E, Thomann AE, Lipsmeier F, Taylor KI, Postuma RB, Cheng W, Lier B, Trundell D, Zago W, Boulay A, Pagano G, Gossens C, Lindemann M
04:45 PM
Duration 10mins Virtual
Satralizumab in patients with neuromyelitis optica spectrum disorder (NMOSD) and concomitant autoimmune disease (CAID)
Anthony Traboulsee, Michael R. Yeaman, Brian G. Weinshenker, Jacqueline Palace, Ingo Kleiter, Xiujing Kou, Daniela Stokmaier, Kristina Weber, Kazuo Fujihara, Takashi Yamamura
Duration 10mins Virtual
Efficacy and safety of satralizumab in adults with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): Results from the phase 3 SAkura studies
Jeffrey L. Bennett, Edward Fox, Benjamin Greenberg, Brian G. Weinshenker, Kathleen Blondeau, Kristina Weber, Shervin Gholizadeh, Daniela Stokmaier, H.-Christian von Büdingen, Anthony Traboulsee
05:00 PM
Duration 10mins Virtual
SUNFISH Part 2: 24-month efficacy and safety of risdiplam▼ in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA)
Nascimento A, Day JW, Deconinick N, Mazzone E, Oskoui M, Saito K, Vuillerot C, Baranello G, Boespflug-Tanguy O, Goemans N, Kirschner J, Kostera-Pruszcyck A, Servais L, Gerber M, Gorni K, Kletzl H, Martin C, Scalco RS, Staunton H, Yeung WY, Mercuri E on behalf of the SUNFISH working group
08:30 AM
Duration 10mins Virtual
COVID-19 Risk Factors in People with Multiple Sclerosis Treated with Ocrelizumab▼
SL Hauser, R Gold, G Cutter, K Fitovski, HM Schneble, L Whitley, N Jessop, A Sauter
Coming soon